<DOC>
	<DOCNO>NCT01893528</DOCNO>
	<brief_summary>This phase 1 , randomize , double-blind , placebo-controlled first-in-human ( FIH ) study assess safety tolerability ascend single dos REGN2009 administer healthy volunteer .</brief_summary>
	<brief_title>Study Assess Safety Tolerability Ascending Single Doses REGN2009 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>1 . Healthy men woman age 18 65 year inclusive 2 . Body mass index 18.0 kg/m^2 30.0 kg/m^2 , inclusive 1 . Pregnant breastfeed woman 2 . Any clinically significant abnormality observe screen ( day 21 day 2 ) 3 . Known history human immunodeficiency virus ( HIV ) antibody ; and/or positive hepatitis B surface antigen , and/or positive hepatitis C antibody screen visit 4 . History drug alcohol abuse within year prior screen visit ( day 21 day 2 ) 5 . Hospitalization reason within 60 day screen visit ( day 21 day 2 ) 6 . Participation clinical research study within 30 day screen visit ( day 21 day 2 ) within 5 halflives investigational drug therapy study ( whichever longer ) 7 . History hypersensitivity reaction doxycycline similar compound 8 . Any medical psychiatric condition , opinion investigator , would place subject risk , interfere participation study interfere interpretation study result 9 . Previous adverse experience biological investigational therapeutic agent 10 . Sexually active men woman childbearing potential unwilling practice adequate contraception study The information intend contain consideration relevant patient 's potential participation clinical trial inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>